Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 5/20 | 0.38 |
| ▸ | NOS1 | P29475 | 5/20 | 0.38 |
| ▸ | NOS2 | P35228 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL13386458 | 0.96 | NOS3 (0.41) | NOS3NOS1NOS2ALDH1A1TRIM24 | |
| SCHEMBL3667791 | 0.96 | — | — | |
| SCHEMBL155648 | 0.96 | — | — | |
| SCHEMBL2800157 | 0.96 | — | — | |
| Methane SCHEMBL15013268 | 0.92 | NOS3 (0.38) | NOS3NOS1NOS2ALDH1A1TRIM24 | |
| SCHEMBL583260 | 0.91 | — | — | |
| SCHEMBL143894 | 0.76 | — | — | |
| SCHEMBL13348019 | 0.70 | NOS3 (0.40) | NOS3NOS1NOS2ALDH1A1TRIM24 | |
| SCHEMBL3676789 | 0.70 | NOS3 (0.40) | NOS3NOS1NOS2ALDH1A1TRIM24 | |
| SCHEMBL12514471 | 0.70 | NOS3 (0.40) | NOS3NOS1NOS2ALDH1A1TRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745138-A1 | THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| EP-4745135-A1 | COMPOUND BASED ON THIO-GLUTARIMIDO ISOINDOLINONE SKELETON AND USE THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| EP-4722207-A1 | OXOISOINDOLINYL-SUBSTITUTED TETRAHYDROPYRIMIDINEDIONE DERIVATIVE AND USE THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12582641-B2 | Sulfur-containing compound based on glutarimide skeleton and application thereof | SHANGHAITECH UNIVERSITY (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4678638-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250243210-A1 | CRBN E3 LIGASE LIGAND COMPOUND, PROTEIN DEGRADER DEVELOPED BASED THEREON AND THEIR APPLICATIONS | GLUETACS THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-20250144223-A1 | PROTEIN DEGRADATION COMPOUND BASED ON NAMPT TARGET PROTEIN AND APPLICATION THEREOF | GLUETACS THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| WO-2025026422-A1 | ARYL OR HETEROARYL SUBSTITUTED GLUTARIMIDE DERIVATIVE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2025-02-06 | — | — | WO | disclosed |
| WO-2025016351-A1 | COMPOUND BASED ON THIO-GLUTARIMIDO ISOINDOLINONE SKELETON AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2025-01-23 | — | — | WO | disclosed |
| WO-2025016350-A1 | THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2025-01-23 | — | — | WO | disclosed |
| EP-2459537-A2 | METHOD AND SUBSTANCES FOR PREPARATION OF N-SUBSTITUTED PYRIDINIUM COMPOUNDS | Roche Diagnostics GmbH (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-8071624-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| WO-2011012269-A2 | METHOD AND SUBSTANCES FOR PREPARATION OF N-SUBSTITUTED PYRIDINIUM COMPOUNDS | ROCHE DIAGNOSTICS GMBH (DE) | 2011-02-03 | — | — | WO | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1742624-A2 | DOPAMINE-AGONIST COMBINATION THERAPY WITH SEDATIVES FOR IMPROVING SLEEP QUALITY | Sepracor, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | INCYTE CORPORATION | 2006-01-05 | — | — | US | disclosed |
| WO-2005079851-A2 | DOPAMINE-AGONIST COMBINATION THERAPY WITH SEDATIVES FOR IMPROVING SLEEP QUALITY | SEPRACOR, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-0068806-A2 | Basic acyl amides of (5-amino-1,3-dialkylpyrazol-4-yl)(aryl)methanones, processes for their production, and pharmaceutical compositions containing such compounds | WARNER-LAMBERT COMPANY (US) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582641-B2 | Sulfur-containing compound based on glutarimide skeleton and application thereof | SUCNR1, SRD5A1, GLS | NOS3 1760/4885NOS1 1421/4885NOS2 2632/4885 |
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | HSD11B1, CYP11B1, HSD3B1 | NOS3 890/4885NOS1 419/4885NOS2 1108/4885 |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | HSD11B1, HSD3B1, HSD11B2 | NOS3 829/4885NOS1 345/4885NOS2 990/4885 |
| US-20250144223-A1 | PROTEIN DEGRADATION COMPOUND BASED ON NAMPT TARGET PROTEIN AND APPLICATION THEREOF | NAMPT, NAPRT, PCMT1 | NOS3 2796/4885NOS1 2485/4885NOS2 3082/4885 |
| US-20250243210-A1 | CRBN E3 LIGASE LIGAND COMPOUND, PROTEIN DEGRADER DEVELOPED BASED THEREON AND THEIR APPLICATIONS | CRBN, MDM2, CBLB | NOS3 2858/4885NOS1 3046/4885NOS2 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.